Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Wednesday, Sep 06, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Overall, patients with HER2-positive breast cancer do well with available regimens. Using trastuzumab (Herceptin) in combination with chemotherapy for this patient population significantly improves disease-free and overall survival, states Tolaney.

How to best add pertuzumab (Perjeta) to the treatment landscape and which patients should receive it are significant questions that many physicians would like to see answered, explains Tolaney.



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Overall, patients with HER2-positive breast cancer do well with available regimens. Using trastuzumab (Herceptin) in combination with chemotherapy for this patient population significantly improves disease-free and overall survival, states Tolaney.

How to best add pertuzumab (Perjeta) to the treatment landscape and which patients should receive it are significant questions that many physicians would like to see answered, explains Tolaney.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x